ArticleFrontiers in pharmacology2017
A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- The Post-Authorisation Maze: Mapping of European Pharmaceutical Market Access Pathways in the Early JCA Era.Journal of market access & health policy · 2026Article
- The European Union's Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks.Journal of market access & health policy · 2026Article
- Comparing National Health Technology Assessment approaches and the new European Joint Clinical Assessment framework: The case of onco-hematological medicines.European journal of clinical pharmacology · 2026Article
- France versus Germany: differences and similarities in determining the added therapeutic value of medicines.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland.PharmacoEconomics - open · 2026Article
- Challenges and reforms in Spain's health technology assessment system: analysis of criteria influencing medicines' reimbursement decisions between 2019 and 2022 in Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Exploring the Pharmacogenetic Landscape: Identification of Clinically Relevant Genotypes by a Nation-Wide Medical Testing Laboratory in Romania.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Should annual cost of the drug inform reimbursement decisions? A perspective from China's healthcare security system.Frontiers in public health · 2025Article
- Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy.Health research policy and systems · 2024Article
- The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries' past health technology assessments.International journal of technology assessment in health care · 2023Article
- The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer.Journal of pharmaceutical policy and practice · 2023Review
- The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries.Frontiers in pharmacology · 2023Article
- What is the value of explicit priority setting for health interventions? A simulation study.Health care management science · 2022Article
- Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- How can a joint European health technology assessment provide an 'additional benefit' over the current standard of national assessments? : Insights generated from a multi-stakeholder survey in hematology/oncology.Health economics review · 2022Article
- Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.Frontiers in medical technology · 2022Article
- Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making.PharmacoEconomics - open · 2021Article
- National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison.PharmacoEconomics - open · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.